39 research outputs found
Absence of Plekhg5 Results in Myelin Infoldings Corresponding to an Impaired Schwann Cell Autophagy, and a Reduced T-Cell Infiltration Into Peripheral Nerves
LĂŒningschrör P, Slotta C, Heimann P, et al. Absence of Plekhg5 Results in Myelin Infoldings Corresponding to an Impaired Schwann Cell Autophagy, and a Reduced T-Cell Infiltration Into Peripheral Nerves. Frontiers in Cellular Neuroscience. 2020;14: 185.Inflammation and dysregulation of the immune system are hallmarks of several neurodegenerative diseases. An activated immune response is considered to be the cause of myelin breakdown in demyelinating disorders. In the peripheral nervous system (PNS), myelin can be degraded in an autophagy-dependent manner directly by Schwann cells or by macrophages, which are modulated by T-lymphocytes. Here, we show that the NF-ÎșB activator Pleckstrin homology containing family member 5 (Plekhg5) is involved in the regulation of both Schwann cell autophagy and recruitment of T-lymphocytes in peripheral nerves during motoneuron disease. Plekhg5-deficient mice show defective axon/Schwann cell units characterized by myelin infoldings in peripheral nerves. Even at late stages, Plekhg5-deficient mice do not show any signs of demyelination and inflammation. Using RNAseq, we identified a transcriptional signature for an impaired immune response in sciatic nerves, which manifested in a reduced number of CD4+ and CD8+ T-cells. These findings identify Plekhg5 as a promising target to impede myelin breakdown in demyelinating PNS disorders
Use of Multiple Metabolic and Genetic Markers to Improve the Prediction of Type 2 Diabetes: the EPIC-Potsdam Study
OBJECTIVE â We investigated whether metabolic biomarkers and single nucleotide poly-morphisms (SNPs) improve diabetes prediction beyond age, anthropometry, and lifestyle risk factors. RESEARCH DESIGN AND METHODS â A case-cohort study within a prospective study was designed. We randomly selected a subcohort (n 2,500) from 26,444 participants, of whom 1,962 were diabetes free at baseline. Of the 801 incident type 2 diabetes cases identified in the cohort during 7 years of follow-up, 579 remained for analyses after exclusions. Prediction models were compared by receiver operatoring characteristic (ROC) curve and integrated dis-crimination improvement. RESULTS â Case-control discrimination by the lifestyle characteristics (ROC-AUC: 0.8465) im-proved with plasma glucose (ROC-AUC: 0.8672, P 0.001) and A1C (ROC-AUC: 0.8859, P 0.001). ROC-AUC further improved with HDL cholesterol, triglycerides, -glutamyltransferase, and alanine aminotransferase (0.9000, P 0.002). Twenty SNPs did not improve discrimination beyond these characteristics (P 0.69). CONCLUSIONS â Metabolic markers, but not genotyping for 20 diabetogenic SNPs, im-prove discrimination of incident type 2 diabetes beyond lifestyle risk factors. Diabetes Care 32:2116â2119, 2009 A ccurate identification of individualswho are at increased risk for type 2diabetes is a requirement for a tar-geted prevention. We therefore tested whether metabolic and genetic markers add substantial prognostic information to age, anthropometry, and lifestyle characteristics
final results of a noninterventional study
Background Data are limited regarding routine use of everolimus after initial
vascular endothelial growth factor (VEGF)âtargeted therapy. The aim of this
prospective, noninterventional, observational study was to assess efficacy and
safety of everolimus after initial VEGF-targeted treatment in patients with
metastatic renal cell carcinoma (mRCC) in routine clinical settings. Methods
Everolimus was administered per routine clinical practice. Patients with mRCC
of any histology from 116 active sites in Germany were included. The main
objective was to determine everolimus efficacy in time to progression (TTP).
Progression-free survival (PFS), treatment duration, tumor response, adherence
to everolimus regimen, treatment after everolimus, and safety were also
assessed. Results In the total population (Nâ=â334), median follow-up was 5.2
months (range, 0â32 months). Median treatment duration (safety population, nâ=
318) was 6.5 months (95% confidence interval [CI], 5â8 months). Median TTP and
median PFS were similar in populations investigated. In patients who received
everolimus as second-line treatment (nâ=â211), median (95% CI) TTP was 7.1
months (5â9 months) and median PFS was 6.9 months (5â9 months). Commonly
reported adverse events (safety population, nâ=â318) were dyspnea (17%),
anemia (15%), and fatigue (12%). Limitations of the noninterventional design
should be considered. Conclusions This study reflects routine clinical use of
everolimus in a large sample of patients with mRCC. Favorable efficacy and
safety were seen for everolimus after previous therapy with one VEGF-targeted
agent. Results of this study confirm everolimus as one of the standard options
in second-line therapy for patients with mRCC. Novartis study code,
CRAD001LD27: VFA registry for noninterventional studies
(http://www.vfa.de/de/forschung/nisdb/ webcite)
results of a randomized controlled trial
Bile acids (BAs) are increasingly recognised as metabolic regulators,
potentially improving insulin sensitivity following bariatric surgery.
However, physiological relevance of such observations remains unknown. Hence,
we analysed serum BA composition and associated gut-derived hormone levels
following lifestyle-induced weight loss in individuals with metabolic syndrome
(MetS). 74 non-smoking men (45â55 yr) with MetS were randomised to a
lifestyle-induced weight loss program (supervision via telemonitoring) or to a
control arm. Before and after a 6 months intervention period clinical and
laboratory parameters, body composition, serum BA profile, FGF-19, and GLP-1
concentrations were determined in fasting blood samples. 30 participants in
the control and 33 participants in the treatment arm completed the study and
were included in the data analysis. In participants of the treatment arm
lifestyle-induced weight loss resulted in markedly improved insulin
sensitivity. Serum levels of BA species and total GLP-1 decreased, while
FGF-19 remained stable. Serum BA composition changed towards an increased 12α-
hydroxylated/non-12α-hydroxylated ratio. None of these parameters changed in
participants of the control arm. Our results demonstrate that improved
metabolic control by lifestyle modifications lowers serum levels of BAs and
GLP-1 and changes serum BA composition towards an increased 12α/non-12α ratio
(ICTRP Trial Number: U1111-1158-3672)
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study
Background: Data are limited regarding routine use of everolimus after initial vascular endothelial growth factor (VEGF)-targeted therapy. The aim of this prospective, noninterventional, observational study was to assess efficacy and safety of everolimus after initial VEGF-targeted treatment in patients with metastatic renal cell carcinoma (mRCC) in routine clinical settings. Methods: Everolimus was administered per routine clinical practice. Patients with mRCC of any histology from 116 active sites in Germany were included. The main objective was to determine everolimus efficacy in time to progression (TTP). Progression-free survival (PFS), treatment duration, tumor response, adherence to everolimus regimen, treatment after everolimus, and safety were also assessed. Results: In the total population (N = 334),median follow-up was 5.2 months (range, 0-32 months). Median treatment duration (safety population, n = 318) was 6.5 months (95% confidence interval [CI], 5-8 months). Median TTP and median PFS were similar in populations investigated. In patients who received everolimus as second-line treatment (n = 211),median (95% CI) TTP was 7.1 months (5-9 months) and median PFS was 6.9 months (5-9 months). Commonly reported adverse events (safety population, n = 318) were dyspnea (17%),anemia (15%), and fatigue (12%). Limitations of the noninterventional design should be considered. Conclusions: This study reflects routine clinical use of everolimus in a large sample of patients with mRCC. Favorable efficacy and safety were seen for everolimus after previous therapy with one VEGF-targeted agent. Results of this study confirm everolimus as one of the standard options in second-line therapy for patients with mRCC
Myelination generates aberrant ultrastructure that is resolved by microglia
To enable rapid propagation of action potentials, axons are ensheathed by myelin, a multilayered insulating membrane formed by oligodendrocytes. Most of the myelin is generated early in development, resulting in the generation of long-lasting stable membrane structures. Here, we explored structural and dynamic changes in central nervous system myelin during development. To achieve this, we performed an ultrastructural analysis of mouse optic nerves by serial block face scanning electron microscopy (SBF-SEM) and confocal time-lapse imaging in the zebrafish spinal cord. We found that myelin undergoes extensive ultrastructural changes during early postnatal development. Myelin degeneration profiles were engulfed and phagocytosed by microglia using exposed phosphatidylserine as one âeat meâ signal. In contrast, retractions of entire myelin sheaths occurred independently of microglia and involved uptake of myelin by the oligodendrocyte itself. Our findings show that the generation of myelin early in development is an inaccurate process associated with aberrant ultrastructural features that require substantial refinement.</p
Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study
Background: Everolimus is approved for treatment of anti-vascularendothelial growth factor (VEGF)-refractory patients with metastaticrenal cell carcinoma (mRCC). Clinical trials rarely mirror treatmentreality. Thus, a broader evaluation of everolimus is valuable forroutine use. Patients and Methods: A German multicenternon-interventional study documented mRCC patients starting everolimusafter failure of initial VEGF-targeted therapy. Primary endpoint waseffectiveness, defined as time to progression (TIP) according toinvestigator assessment (time from first dose to progression). Results:Of 382 documented patients, 196 were included in this interim analysis
Associations between Dietary Patterns and Bile AcidsâResults from a Cross-Sectional Study in Vegans and Omnivores
Bile acids play an active role in fat metabolism and, in high-fat diets, elevated concentrations of fecal bile acids may be related to an increased risk of colorectal cancer. This study investigated concentrations of fecal and serum bile acids in 36 vegans and 36 omnivores. The reduced rank regression was used to identify dietary patterns associated with fecal bile acids. Dietary patterns were derived with secondary and conjugated fecal bile acids as response variables and 53 food groups as predictors. Vegans had higher fiber (p < 0.01) and lower fat (p = 0.0024) intake than omnivores. In serum, primary and glycine-conjugated bile acids were higher in vegans than in omnivores (p ≤ 0.01). All fecal bile acids were significantly lower in vegans compared to omnivores (p < 0.01). Processed meat, fried potatoes, fish, margarine, and coffee contributed most positively, whereas muesli most negatively to a dietary pattern that was directly associated with all fecal bile acids. According to the pattern, fat intake was positively and fiber intake was inversely correlated with bile acids. The findings contribute to the evidence that, in particular, animal products and fat may play a part in higher levels of fecal bile acids